Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Investor Presentation (January 2022)
36 slides from Camlin Fine Sciences's investor presentation, Jan 5, 2022
Slide 1: Exchange intimation of analyst/investor meeting schedule
January 5, 2022 To, To, BSE Limited, Listing Department, 25, P. J. Towers, National Stock Exchange of India Ltd., Dalal Street, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai‐ 400051 Ref: Company Scrip Code: 532834 Ref: Symbol: CAMLINFINE || Series: EQ Sub: Intimation o
Slide 2: Camlin Fine Sciences Ltd. Investor Presentation – January 2022
Camlin Fine Sciences Ltd. Investor Presentation – January 2022
Slide 3: Safe Harbour
Safe Harbour 5 This presentation and the accompanying slides (the “Presentation”), which have been prepared by Camlin Fine Sciences Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for a
Slide 4: Bringing Science to Everyday Life
B r i n g i n g S c i e n c e t o E ve r y d ay L i fe #start your story
Slide 5: Company Overview
Company Overview 5 Camlin Fine Sciences Ltd. is a vertically integrated company, engaged in the research, development, manufacturing, commercializing, and marketing of specialty chemicals and blends. 2006 Leading Preferred manufacturer of Partner for Established Antioxidants Customised Products Rs 1
Slide 6: Business Verticals & Industries Served
Business Verticals & Industries Served 5 Business Mix FY21* 16% <2% 29% 53% Sales Mix End User Industries › Feed & Food › Functional Foods › Pharma Intermediates › Food › Personal Care & Home Care › Livestock Feed › Petrochemicals › Animal Nutrition › Flavours & Fragrances › Dietary Supplements › Dy
Slide 7: Strategically Located
Strategically Located 5 80+ Countries Presence USA Italy China 14% : 86% Mexico Cuba India Domestic : Exports Dominican Republic Contribution* Gautemala Singapore Colombia Peru Brazil 1,000+ Chille Argentina Customers CFS Wanglong CFS North CFS Dresen (Dresen ` CFS do Brasil Ltda. CFS Europe SpA Cam
Slide 8: Global Research & Development
Global Research & Development 5 Application Labs › Develops customized blends for various applications › Provides technical assistance and development support to customers • Mexico City › Tests of defined performance parameters • Des Moines, USA › Conducts stability studies for various products of s
Slide 9: Over The Decades, A Prestigious Brand Has Emerged
Over The Decades,A Prestigious Brand Has Emerged 5 FY94 FY07 FY12 FY14 › Camlin Fine Chemical division › Camlin Fine Sciences Ltd. was › Acquired Borregaard Italia › Introduced extensive range of incorporated in Camlin Ltd. to formed after de-merging SpA, a manufacturing facility in performance chem
Slide 10: Complex Chemistry With High Barriers
Complex Chemistry With High Barriers 5 Long Gestation Period High Replacement Cost Tight Regulations Our global presence, growing scale, Complying with a wide range of laws, Customer acquisition takes a long reliable supply chain, rationalized cost regulations and practices, including time, thus the
Slide 11: Key Strengths
Key Strengths 5 1 Leading, global player in shelf-life solutions across food, feed, pet-food and Biodiesel 2 Local presence in major global markets 3 Advanced R&D facilities & Application Labs 4 Proven ability to acquire and improve business performance 5 Vertically integrated across the value chain
Slide 12: Business Overview
Business Overview #start your story
Slide 13: Shelf Life Solutions
Shelf Life Solutions 5 End User Industries Total Operational Revenue (INR Mn) Product portfolio 6,171 5,516 Foods 4,856 Antioxidants (straights) Blends & Other Additives 2,860 2,381 3,606 2,248 Established player in the global market with over 2,994 Pet Food 1,571 30 years of experience 1,667 3,135
Slide 14: Performance Chemicals
Performance Chemicals 5 End User Industries › Performance Chemicals are specialty chemicals sold on the basis of their Total Operational Revenue (INR Mn) performance for specific industrial applications › Entered into a long-term preferred supply agreement with Lockheed Martin Advanced Energy Storag
Slide 15: Aroma Ingredients
Aroma Ingredients 5 End User Industries › CFS produces Vanillin through the Catechol route and its brand is one of Total Operational Revenue (INR Mn) the most trusted by the Food and Flavours Industry. › Vanillin is a synthetic substitute to natural vanilla derived from vanilla beans, which is very
Slide 16: Health & Wellness
Health & Wellness 5 End User Industries › Launched in 2019 to cater to the rising awareness and growing demand for natural products. › Offers nutraceutical products derived by plant extraction and fermentation such as natural colours, Pet Food functional ingredients, plant-based extracts in natural
Slide 17: CFS 2.0
CFS 2.0 #start your story
Slide 18: CFS 2.0
CFS 2.0 5 CFS CFS 1.0 2.0 Further Improving Advancing Expansion in Preparing Operational Growth Acceleration Downstream For Future Efficiencies Strategies Products 17
Slide 19: Manufactured In-house: Integration Chain
Integration Chain 5 Phenol Manufactured In-house Hydroquinone Diphenols Catechol Performance Performance Shelf Life Solutions Chemicals Aroma Ingredients Chemicals Ascorbyl Palmitate1 TBHQ MEHQ Guaiacol Guethol BHA Other derivatives of HQ Veratrole Vanillin Other derivatives of Blends Catechol Ethyl
Slide 20: Improving Operational Efficiencies
Improving Operational Efficiencies 5 Key Rational Before Dahej Expansion: After Dahej Expansion: › Backward Integrated through Italy & Dahej Facility › Diphenols were manufactured in Italy and › Diphenol captive requirement in India will be met › Became 2nd largest and lowest-cost transported to man
Slide 21: Well Placed to Expand Downstream Products
Well Placed to Expand Downstream Products 5 Wide Product Basket Key Products Our Presence Hydroquinone Catechol › High Volatile Business › High Volatile Business › Supply Deficit in Global Market › Oversupply in Global Market MEHQ ✓ › High Demand › Moderate Demand BHA ✓ Guaiacol ✓ Ascorbyl Palmitate
Slide 22: Advancing Our Growth Strategy
Advancing Our Growth Strategy 5 › With a diverse product portfolio, worldwide presence, › Commercialization of 10,000 MT greenfield facility at Dahej, continuous focus on R&D, and healthy financial position, CFS is Gujarat, has doubled CFS’ diphenol capacity along with Italy facility well-positioned
Slide 23: Preparing For Future Growth
Preparing For Future Growth 5 Building Additional Multipurpose Plant › Setting up 6,000 MT Vanillin facility at Dahej, Gujarat to make Guaiacol (raw material for Vanillin), Vanillin, Ethyl Vanillin, Methyl Vanillin, and its derivatives › The low-cost Catechol obtained from & the latest Dahej facilit
Slide 24: Way Forward: Acceleration
Way Forward : Acceleration 5 Acceleration SHELF-LIFE SOLUTIONS AROMA INGREDIENTS › Increasing focus on high margin blends and › Setting up 6,000 MT Vanillin facility at Dahej additives › Focusing on cost efficient manufacturing of › Introducing new products, cross-selling Vanillin leading to improve
Slide 25: ESG Highlights
ESG Highlights 5 › Carefully chosen product portfolio to provide environmental benefits addressing large societal challenges like food waste prevention. Environment › CFS is proactively working towards sourcing clean energy from wind energy farm with a capacity of 1.25MW which could replace upto 20%
Slide 26: Key Clients and Certificates
Key Clients and Certificates 5 Key Clients Key Certificates The Brand Names and Logos mentioned are the property of their respective owners and are used here for identification purposes only 25
Slide 27: Board of Directors
Board of Directors 5 Ashish Dandekar Nirmal Momaya Mr. Arjun Dukane Harsha Raghavan Chairman & Managing Director Managing Director Executive Director - Technical Non Executive Non-Independent • BA in Economics and Management studies form • CA with over 25 years of experience in Finance, Taxation, •
Slide 28: Financial Highlights
Financial Highlights #start your story
Slide 29: Q2FY22 Result Highlights
Q2FY22 Result Highlights 5 Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 13.1% 7.3% 3.8% -1.2% Margin 3,112.2 336.4 96.6 2,568.1 227.1 -38.8 Q2FY21 Q2FY22 Q2FY21 Q2FY22 Q2FY21 Q2FY22 15.1% 11.4% 5.4% 3.1% 6,420.5 847.2 302.2 5,625.5 733.1 198.9 H1FY21 H1FY22 H1FY21 H1FY22 H1 FY21 H1 FY22 On
Slide 30: Segmental Highlights
Segmental Highlights 5 Shelf Life Extension (Rs. In Mn) Blends (Rs. In Mn) Total Shelf Life Solution (Rs. In Mn) 2,860 3,311 6,171 3,135 5,516 2,248 2,381 2,608 4,856 2,035 1,887 3,606 1,571 1,574 3,461 FY18 FY19 FY20 FY21 H1FY22 FY18 FY19 FY20 FY21 H1FY22 FY18 FY19 FY20 FY21 H1FY22 Performance Chem
Slide 31: Performance by Subsidiary
Performnce 5 CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 5,798 6,000 2,735 3,762 5,481 2,571 3,296 2,172 3,091 2,771 4,050 1,642 1,513 2,177 2,839 FY18 FY19 FY20 FY21 H1FY22 FY18 FY19 FY20 FY21 H1FY22 FY18 FY19 FY20 FY21 H1FY22 CFS Brazil (Rs. In Mn) CFS Wanglong (Rs. In Mn)
Slide 32: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement 5 Particulars (Rs. In Mn) Q2 FY22 Q2 FY21 YoY H1 FY22 H1 FY21 YoY Revenue from Operation 3,112.2 2,568.1 21.2% 6,420.5 5,625.5 14.1% Raw material consumption 1,709.1 1,200.9 3,539.1 2,833.8 Employee Cost 345.5 284.3 673.1 538.2 Other expenses 830.5 746.5 1,475.2
Slide 33: Consolidated Balance Sheet Statement
Consolidated Balance Sheet Statement 5 Particulars (Rs. In Mn) Sep’21 Mar’21 Particulars (Rs. In Mn) Sep'21 Mar'21 ASSETS Equity & Liabilities Non-Current Assets 7,744.3 6,869.1 EQUITY 7,736.6 7,130.5 Property, Plant and Equipment 4,753.0 4,817.5 Equity Share Capital 127.6 127.5 Capital work-in-prog
Slide 34: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement 5 Particulars (Rs. In Mn) Sep-21 Sep-20 Net Profit Before Tax 333.1 486.8 Adjustments for: Non Cash Items / Other Investment or Financial Items 390.1 564.4 Operating profit before working capital changes 723.2 1051.2 Changes in working capital 83.5 -141.2 Cash genera
Slide 35: Historical Financial Highlights
Historical Financial Highlights 5 Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 5.2% 1.7% 7.7% 12.5% 15.3% -0.8% -3.3% 0.3% 2.8% 5.5% Margin +21% 11,871 10,491 1,819 654 8,922 +59% 7,228 1,307 298 5,469 687 30 282 126 -44 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 -240 FY17 FY18 FY19
Slide 36: Thank You
Thank You Camlin Fine Sciences Ltd. CIN – L74100MH1993PLCO75361 Mr. Santosh Parab- CFO Email – santosh.parab@camlinfs.com www.camlinfs.com #start your story Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Jigar Kavaiya Email – jigar.kavaiya@sgapl.net www.sgapl.net 35
Camlin Fine Sciences — Investor Presentation (January 2022) on 6ix